SCHEMBL5376083

SCHEMBL5376083

O=C1CCN(c2ccccc2)C(=O)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 12/20 1.00
DDB1 Q16531 11/20 1.00
ALOX5 P09917 2/20 0.53
G6PD P11413 1/20 0.53
ALOX15 P16050 1/20 0.53
ALOX12 P18054 1/20 0.53
PTGS1 P23219 1/20 0.53
PTGS2 P35354 1/20 0.53
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 2/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TNKS O95271 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30874155 0.98 CRBN (0.96) CRBNDDB1ALOX5G6PDALOX15
SCHEMBL23142732 0.90 CRBN (0.81) CRBNDDB1ALOX5G6PDALOX15
SCHEMBL21995508 0.89 CRBN (0.80) CRBNDDB1ALOX5G6PDALOX15
SCHEMBL24155474 0.85 CRBN (0.73) CRBNDDB1ALOX15MAPTTDP1
SCHEMBL24155535 0.85 CRBN (0.73) CRBNDDB1GAATNKS
SCHEMBL24156370 0.85 CRBN (0.73) CRBNDDB1ALOX5G6PDALOX15
SCHEMBL23983474 0.81 CRBN (0.71) CRBNDDB1RAB9AKDM4EMAPT
SCHEMBL23120608 0.81 CRBN (0.71) CRBNDDB1ALOX5KDM4EALDH1A1
SCHEMBL21995598 0.81 CRBN (0.71) CRBNDDB1MEN1KMT2AKDM4E
SCHEMBL23134713 0.81 CRBN (0.71) CRBNDDB1ALOX5KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4673438-A1 PROTEOLYSIS-TARGETING CHIMERAS Tocris Cookson Limited (GB) 2026-01-07 EP claimed
CN-120152967-A Bifunctional compounds containing 2, 5-substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway 霖康疗法公司 2025-06-13 CN claimed
WO-2024180157-A1 PROTEOLYSIS-TARGETING CHIMERAS TOCRIS COOKSON LIMITED (GB) 2024-09-06 WO claimed
US-20070208036-A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-09-06 US claimed
US-7230001-B1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-06-12 US claimed
JP-63066173-A None JP disclosed
EP-4673438-A1 PROTEOLYSIS-TARGETING CHIMERAS Tocris Cookson Limited (GB) 2026-01-07 EP disclosed
US-20250354195-A1 METHOD OF SCREENING UNIV DUNDEE (GB) 2025-11-20 US disclosed
US-20250051320-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 US disclosed
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 US disclosed
WO-2024227104-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
WO-2024180157-A1 PROTEOLYSIS-TARGETING CHIMERAS TOCRIS COOKSON LIMITED (GB) 2024-09-06 WO disclosed
US-20200347045-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2020-11-05 US disclosed
US-10800758-B2 Pyrimidine compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-10-13 US disclosed
CN-109641872-A 3- pyridyl group phenyl dihydrouracil compound and application thereof 住友化学株式会社 2019-04-16 CN disclosed
CN-109641872-A 3- pyridyl group phenyl dihydrouracil compound and application thereof 住友化学株式会社 2019-04-16 CN disclosed
US-20070208036-A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-09-06 US disclosed
US-7230001-B1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-06-12 US disclosed
WO-2004009559-A2 DIHYDROURACIL COMPOUNDS AS ANTI-ICTOGENIC OR ANTI-EPILEPTOGENIC AGENTS QUEEN'S UNIVERSITY AT KINGSTON (CA) 2004-01-29 WO disclosed
JP-S6366173-A PRODUCTION OF URACIL DERIVATIVE UENO SEIYAKU OYO KENKYUSHO:KK 1988-03-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347045-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 CRBN 1/4885DDB1 304/4885ALOX5 4795/4885
US-20070208036-A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them ARRB1, NPY1R, ADRB3 CRBN 2351/4885DDB1 2631/4885ALOX5 1246/4885
US-20250051320-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 CRBN 1/4885DDB1 304/4885ALOX5 4795/4885
US-10800758-B2 Pyrimidine compound UMPS, TPMT, TYMS CRBN 4450/4885DDB1 2854/4885ALOX5 1795/4885
US-20250354195-A1 METHOD OF SCREENING PAICS, COASY, ABCG2 CRBN 1827/4885DDB1 797/4885ALOX5 3451/4885
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 CRBN 218/4885DDB1 675/4885ALOX5 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.